NRSN - Neurosense Therapeutics Ltd

NRSN - Neurosense Therapeutics Ltd

https://www.neurosense-tx.com

Recent News

Powered by Alpha Vantage

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - NeuroSense Therapeutics ( NASDAQ:NRSN ) , Primis Finl ( NASDAQ:FRST )

Benzinga • 4 months ago • score: 0.28

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. D. Boral Capital analyst Jason Kolbert initiated coverage on NeuroSense Therapeutics Ltd.

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission - NeuroSense Therapeutics ( NASDAQ:NRSN )

Benzinga • 10 months, 2 weeks ago • score: 0.06

NeuroSense Therapeutics Ltd. NRSN on Monday said it is scheduled for an FDA Type C meeting to discuss the design of its upcoming Phase 3 clinical trial for PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis ( ALS ) . ALS is a fatal type of motor neuron disease.

EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug - NeuroSense Therapeutics ( NASDAQ:NRSN )

Benzinga • 1 year ago • score: 0.16

NeuroSense Therapeutics Ltd. NRSN on Wednesday said it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis ( ALS ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$2.60

52W Low

$0.80

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.57

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.16

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

12.82

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

29.68%

Institutions (25–75% balanced)

1.80%

Shares Outstanding

25,043,300

Float

12,538,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-0.36

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-24.78%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—